Biblio Discovery — Demo Discovery Service

5 hasil untuk "Michael Heuser"

Menampilkan 1–5 · 0,44 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

    Pau Montesinos; Christian Récher; Susana Vives dkk.

    New England Journal of Medicine · 2022 · Inggris · OpenAlex Scopus

    BACKGROUND: -mutated acute myeloid leukemia. METHODS: -mutated acute myeloid leukemia who were ineligible for intensive induction chemotherapy to receive oral ivosidenib (500 mg once daily) and subcutaneous or intravenous azacitidine (75 mg per square meter of body-surface area for 7 days in 28-day…

  2. Artikel Jurnal Teks lengkap

    SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Luca Malcovati; Kristen E. Stevenson; Elli Papaemmanuil dkk.

    Blood · 2020 · Inggris · OpenAlex Scopus

    The 2016 revision of the World Health Organization classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology and molecular genetics. Notwithstanding, the myelodysplastic syndrome (MDS) with isolated del(5q) remains so far the only MDS…

  3. Artikel Jurnal

    2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

    Michael Heuser; Sylvie D. Freeman; Gert Jan Ossenkoppele dkk.

    Blood · 2021 · Inggris · OpenAlex Scopus

    Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing…

  4. Artikel Jurnal

    Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    Elsa Bernard; Heinz Tuechler; Peter L. Greenberg dkk.

    NEJM Evidence · 2022 · Inggris · OpenAlex Scopus

    BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are not yet used in the risk…